Teva’s New CEO Francis: No Revolution, But New Strategy Will Not Be Marginal
Newly Appointed Company Head Speaks For First Time At J.P. Morgan Conference
On the final day of the annual J.P. Morgan Healthcare Conference, Richard Francis, with vast experience at Biogen and Sandoz under his belt, faced investors for the first time as Teva’s CEO, after replacing Kåre Schultz on 1 January.
